Skip to main content
OpenTrials
Completed

NCT Number: NCT00516490

GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles

A single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles was reported to increase pregnancy and birth rates. This study was done to evaluate the reproducibility of previous findings.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Amerikan Hastanesi Tüp Bebek Merkezi

Istanbul, 34365, Turkey (Türkiye)

About this study

GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the long GnRH agonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a long GnRH agonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women undergoing embryo transfer following controlled ovarian hyperstimulation with a long GnRH agonist protocol, oocyte pick-up and ICSI.
  • Embryo transfer performed on day 3.

Exclusion criteria

  • Participation in another trial that was being conducted in our unit at the same time.
  • Preimplantation genetic screening cycles.
  • Day 5 embryo transfers.

Treatment and study plan

Triptorelin acetate

Drug

Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer

Other names: Decapeptyl Ferring GmBH Kiel Germany

Na Cl %0.9

Drug

0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer

Other names: Isotonik NaCl %0.09 Eczacibasi-Baxter Istanbul Turkey

Primary outcomes

  1. Ongoing pregnancy rate beyond 20 weeks

Secondary outcomes

  1. Clinical pregnancy

  2. Embryo implantation rate

Sponsors and collaborators

Lead sponsor

V.K.V. American Hospital, Istanbul

Other

Registry information

Important dates

Study start
2006
Study completion
2007
First posted
Aug 15, 2007
Registry last updated
Aug 15, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.